Last reviewed · How we verify
NCT07204847
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI
trial in NSTEMI in 407 participants. Completed in 20 June 2025.
1 May 2025
Quick facts
| Lead sponsor | University Hospital, Montpellier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 407 |
| Start date | 1 November 2023 |
| Primary completion | 1 May 2025 |
| Estimated completion | 20 June 2025 |
| Sites | 1 location across France |
Conditions studied
- NSTEMI — all drugs for NSTEMI →
- NSTE-ACS (NSTEMI and UA) — all drugs for NSTE-ACS (NSTEMI and UA) →
- NSTEMI - Non-ST-Segment Elevation Myocardial Infarction — all drugs for NSTEMI - Non-ST-Segment Elevation Myocardial Infarction →
Sponsor
University Hospital, Montpellier
Who can join
18 and older, any sex, with NSTEMI or NSTE-ACS (NSTEMI and UA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this multicentric observational study is to evaluate the prognostic influence of adherence or non-adherence to the recommended coronary angiography timeframe (within 24 hours) and the six-month prognosis of the patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07204847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSTEMI
Currently open trials in the same condition.
- NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
- NCT05764057 — DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction · Phase 3 · recruiting
- NCT05800951 — Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock · active not recruiting
- NCT04988672 — OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting W · recruiting
Other University Hospital, Montpellier trials
Trials by the same sponsor.
- NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
- NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
- NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
- NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
- NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07204847 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07204847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing